From the prestigious New England Journal of Medicine:
Despite great expectations and promising results of clinical trials, we still lack sufficient evidence of an effective vaccine against cervical cancer. Several strains of human papillomavirus (HPV) can cause cervical cancer, and two vaccines directed against the currently most important oncogenic strains (i.e., the HPV-16 and HPV-18 serotypes) have been developed. That is the good news. The bad news is that the overall effect of the vaccines on cervical cancer remains unknown.
How will the vaccine affect preadolescent girls, given that the only trials conducted in this cohort have been on the immune response?
Vaccinated women may feel protected from cervical cancer and may be less likely than unvaccinated women to pursue screening.
How will the vaccine affect other oncogenic strains of HPV? If HPV-16 and HPV-18 are effectively suppressed, will there be selective pressure on the remaining strains of HPV? Other strains may emerge as significant oncogenic serotypes.
So why has the AAP made Merck billions by adding this unproven vaccine to it's "recommended" (meaning the doc is going to give it to your daughter unless you put up a stink) schedule? Click HERE for the full article.